TY  - GEN
AU  - Moreau,Philippe
AU  - Masszi,Tamás
AU  - Grzasko,Norbert
AU  - Bahlis,Nizar J
AU  - Hansson,Markus
AU  - Pour,Ludek
AU  - Sandhu,Irwindeep
AU  - Ganly,Peter
AU  - Baker,Bartrum W
AU  - Jackson,Sharon R
AU  - Stoppa,Anne-Marie
AU  - Simpson,David R
AU  - Gimsing,Peter
AU  - Palumbo,Antonio
AU  - Garderet,Laurent
AU  - Cavo,Michele
AU  - Kumar,Shaji
AU  - Touzeau,Cyrille
AU  - Buadi,Francis K
AU  - Laubach,Jacob P
AU  - Berg,Deborah T
AU  - Lin,Jianchang
AU  - Di Bacco,Alessandra
AU  - Hui,Ai-Min
AU  - van de Velde,Helgi
AU  - Richardson,Paul G
TI  - Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
SN  - 1533-4406
PY  - 2016///0505
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Boron Compounds
KW  - administration & dosage
KW  - Dexamethasone
KW  - Disease-Free Survival
KW  - Double-Blind Method
KW  - Exanthema
KW  - chemically induced
KW  - Glycine
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Proportional Hazards Models
KW  - Quality of Life
KW  - Thalidomide
KW  - Thrombocytopenia
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1056/NEJMoa1516282
ER  -